Treatment options in renal cell carcinoma: Past, present and future Journal Article
| Authors: | Oudard, S.; George, D.; Medioni, J.; Motzer, R. |
| Article Title: | Treatment options in renal cell carcinoma: Past, present and future |
| Abstract: | Cytokine therapies have been the standard of care in metastatic renal cell carcinoma (RCC). However, these agents only provide clinical benefit to a small subset of patients and are associated with significant toxicity. A better understanding of the molecular biology of RCC has identified the vascular endothelial growth factor (VEGF) and platelet-derived growth factor signalling pathways as rational targets for anticancer therapy. The multitargeted receptor tyrosine kinase inhibitors sunitinib and sorafenib have both demonstrated improved efficacy as second-line therapy in patients with RCC. Sunitinib has also been shown to be effective in the first-line setting, and has recently received European Union approval as first-line treatment for advanced and/or metastatic RCC. There is also recent evidence that temsirolimus (an inhibitor of the mammalian target of rapamycin) and bevacizumab (a mAb targeted against VEGF) may provide benefits in the first-line treatment setting. These results confirm that inhibiting these tumour targets is a feasible approach to treatment and provides a more positive outlook for the future management of metastatic RCC. © 2007 European Society for Medical Oncology. |
| Keywords: | unclassified drug; overall survival; clinical trial; drug tolerability; fatigue; review; sorafenib; bevacizumab; erlotinib; fluorouracil; placebo; sunitinib; cancer growth; diarrhea; drug dose comparison; drug dose reduction; drug efficacy; drug safety; drug withdrawal; hypertension; hypophosphatemia; monotherapy; unspecified side effect; benzenesulfonates; pyridines; conference paper; drug targeting; alpha interferon; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; disease free survival; drug megadose; metabolism; gastrointestinal stromal tumor; imatinib; alpha2b interferon; carboplatin; interleukin 2; low drug dose; drug eruption; multiple cycle treatment; anemia; leukopenia; lung non small cell cancer; tumor regression; renal cell carcinoma; kidney carcinoma; kidney neoplasms; nephrectomy; vinblastine; irinotecan; monoclonal antibody; temsirolimus; asthenia; drug dose escalation; drug fever; hyperglycemia; malaise; cytokine; cytokines; antibodies, monoclonal; thorax pain; kidney tumor; carcinoma, renal cell; dosage schedule comparison; evening dosage; morning dosage; folinic acid; drug response; gefitinib; drug derivative; skin disease; maximum tolerated dose; colon carcinoma; drug dose increase; indoles; pyrroles; rectum carcinoma; hand foot syndrome; indole derivative; epistaxis; proteinuria; rapamycin; lapatinib; sirolimus; hypertriglyceridemia; pyrrole derivative; benzenesulfonic acid derivative; pyridine derivative; desquamation; receptor tyrosine kinase inhibitor; recombinant alpha interferon; torsel |
| Journal Title: | Annals of Oncology |
| Volume: | 18 |
| Issue: | Suppl. 10 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2007-09-01 |
| Start Page: | x25 |
| End Page: | x31 |
| Language: | English |
| DOI: | 10.1093/annonc/mdm411 |
| PUBMED: | 17761720 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 23" - "Export Date: 17 November 2011" - "CODEN: ANONE" - "Source: Scopus" |
